Home > Boards > US Listed > Medical - Healthcare > Mylan Inc. (MYL)

MYL acquires European rights to Fujifilm’s Humira FoB: #msg-139952524.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 721
Posts 108,625
Boards Moderated 21
Alias Born 09/05/02
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 1:09:35 PM
Novartis to Supply EpiPen Alternate to U.S. Pharmacies -Reuters Dow Jones News - 7/9/2019 7:30:00 PM
Mylan and Atomo Diagnostics Announce WHO Prequalification Approval for Mylan HIV Self Test PR Newswire (US) - 7/8/2019 12:42:00 PM
Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors GlobeNewswire Inc. - 6/25/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/21/2019 5:02:33 PM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/13/2019 12:59:29 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/7/2019 1:30:36 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 5/31/2019 7:14:02 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/24/2019 5:13:35 PM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic S... PR Newswire (US) - 5/18/2019 10:45:00 AM
Mylan to Host Investor Day on July 31, 2019 in New York City PR Newswire (US) - 5/17/2019 8:00:00 AM
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the... PR Newswire (US) - 5/15/2019 5:01:00 PM
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets PR Newswire (US) - 5/10/2019 9:45:00 AM
Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire (US) - 5/10/2019 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/10/2019 6:08:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 11:07:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 8:37:17 AM
Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance PR Newswire (US) - 5/7/2019 8:30:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2019 4:44:34 PM
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019 PR Newswire (US) - 4/26/2019 7:30:00 AM
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens ... PR Newswire (US) - 4/18/2019 8:00:00 AM
DewDiligence Member Level  Wednesday, 04/11/18 10:09:49 AM
Re: None
Post # of 141 
MYL acquires European rights to Fujifilm’s Humira FoB: #msg-139952524.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist